Tesamorelin: The "Growth Hormone Commander" Reshaping Metabolic Health
I. Product Origin
Tesamorelin is a synthetic peptide developed by the Canadian biopharmaceutical company Theratechnologies. It is an analog of human growth hormone-releasing factor (GHRH), composed of 44 amino acids, and modified at the N-terminus with a trans-3-hexenoyl group to enhance its stability. In November 2010, it was first approved by the US FDA under the brand name Egrifta, specifically for the treatment of lipid metabolism disorders caused by antiretroviral therapy (ART) in HIV-infected individuals, particularly the abnormal accumulation of abdominal visceral fat. In 2025, its upgraded formulation, EGRIFTA WR™, was approved, optimizing the dosing frequency from once daily to once weekly, significantly improving patient experience and treatment adherence.
II. Product Parameters
Generic Name: Tesamorelin
CAS Number: 901758-09-6 / 218949-48-5
Molecular Formula: C₂₂₁H₃₆₆N₇₂O₆₇S
Molecular Weight: Approx. 5136 Da Amino acid sequence: trans-3-hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH₂ Appearance: White to off-white lyophilized powder Purity: ≥98% (HPLC) Storage conditions: Unreconstituted powder should be stored at -20℃ protected from light; reconstituted solution should be refrigerated or stored according to the instructions.
III. Core Functions
Stimulates Endogenous GH Secretion: As an agonist of growth hormone-releasing factor (GHRF), it specifically acts on the pituitary gland, pulsatilely stimulating the synthesis and release of endogenous growth hormone (GH).
Precisely Targets Visceral Fat: By increasing GH and insulin-like growth factor-1 (IGF-1) levels, it activates lipases, selectively mobilizing and reducing deep abdominal visceral fat tissue (VAT), rather than subcutaneous fat.
Improves Body Composition: While reducing fat, it promotes protein synthesis, helping to increase lean body mass (muscle mass), thereby reshaping a healthier body composition.
Regulates Metabolic Indicators: It can significantly reduce blood triglyceride levels, improve insulin resistance, and has a positive therapeutic effect on non-alcoholic fatty liver disease (NAFLD).
IV. Core Advantages
High Selectivity: Unlike traditional weight-loss drugs, it does not suppress appetite but precisely targets the most harmful visceral fat, achieving the ideal effect of "fat reduction without muscle loss."
Physiological Regulation: By stimulating the pituitary gland to secrete GH, it preserves the body's normal negative feedback regulatory mechanism, resulting in higher safety and fewer side effects compared to direct injection of exogenous growth hormone.
Cardiovascular Benefit Potential: Clinical studies have confirmed that reducing visceral fat can effectively improve multiple cardiovascular risk markers, such as reducing inflammatory factors and improving lipid profiles, bringing long-term health benefits beyond appearance to patients.
Treatment Upgrade: The launch of the new generation EGRIFTA WR™ formula reduces the injection frequency to once a week, significantly simplifying the treatment process and improving patients' quality of life.
V. Applicable Scenarios
HIV-related Lipid Metabolism Disorders: This is its only FDA-approved indication, specifically for the treatment of central abdominal obesity in HIV-infected individuals due to long-term medication use.
Metabolic Syndrome Research: Used to explore the role and intervention strategies of the growth hormone axis in metabolic diseases such as insulin resistance, hyperlipidemia, and fatty liver.
Body Composition Remodeling Research: As a tool drug, it studies how to achieve the balance between fat and muscle through endocrine regulation, providing new insights for anti-aging and sports medicine.
Liver Disease Research: Exploring its clinical application potential in reducing hepatic fat deposition and slowing the progression of liver fibrosis.
VI. Precautions
Strictly follow doctor's instructions: This product is a prescription drug and must be used under the guidance of a physician. Self-purchase and use are strictly prohibited, especially for general weight loss.
Glucose Monitoring: Temorelin may cause elevated blood glucose levels. Fasting blood glucose and glycated hemoglobin (HbA1c) should be monitored regularly during treatment. Use with caution in diabetic patients.
Contraindications: This product is contraindicated in patients with hypersensitivity to any of its components, patients with active malignant tumors, pregnant and lactating women, and patients with hypothalamic-pituitary axis dysfunction.
Adverse Reactions: Common adverse reactions include arthralgia, injection site reaction, limb pain, peripheral edema, and myalgia, usually mild to moderate.
Say goodbye to central obesity and regain metabolic renewal-Temorelin, the intelligent growth hormone regulator with precise control.
VII. Success Stories
Case A: Stubborn Visceral Fat in a Middle-Aged Man (Most Common Client Type)
• Condition: 43 years old, sedentary lifestyle, beer belly, waist circumference 98cm, diet and exercise ineffective
• Use: Tesamorelin 2mg/day, 26 weeks
• Results:
◦ Waist circumference from 98cm → 89cm (reduction of 9cm)
◦ Visceral fat reduced by 17%
◦ Improved energy, better sleep, improved blood lipids
◦ Weight remained almost unchanged, but the abdomen became noticeably softer and the waistline became more defined
Case B: Metabolic Syndrome + Fatty Liver in a 52-Year-Old Woman
• Condition: Abdominal obesity, fatty liver, high triglycerides
• Use: 2mg/day, 20 weeks
• Results:
◦ Visceral fat reduced by 15%
◦ Fatty liver improved from moderate to mild
◦ Triglycerides decreased by 23%
◦ Improved skin firmness, reduced fatigue
Case C: Long-Term Fitness Enthusiasts with Stubborn Lower Abdominal Fat (Fitness Enthusiasts)
• Condition: Body fat 18%, but lower abdomen hard and visceral fat high
• Usage: 2mg/day, 12 weeks + regular training
• Results:
◦ Lower abdominal fat significantly softened and thinned
◦ Abdominal muscle definition began to appear
◦ Faster strength recovery, no muscle loss
Meticulous craftsmanship in peptide research, quality is the foundation of excellence.
Focusing on high-end peptide raw materials, meticulous craftsmanship ensures high quality.
Source peptide factory, high purity for greater reliability.
Hot Tags: Peptide drug Tesamorelin 2mg/vial CAS: 218949-48-5, China Peptide drug Tesamorelin 2mg/vial CAS: 218949-48-5 manufacturers, suppliers, factory
